http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2354457-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a910d33c239980f3a705e312c5bad6a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 |
| filingDate | 2006-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2011-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1237042c631dc381f80c33b943103269 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e102e3b5531be085364c075cfba678e2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_26f80de801c1e6e2ce59c816fa56e07b |
| publicationDate | 2011-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2354457-T3 |
| titleOfInvention | COMPOUNDS OF 4- (1H-INDAZOL-5-IL-AMINO) -CHINAZOLINE AS INHIBITORS OF THE ERBB RECEIVER OF THYROSINE KINASE FOR THE TREATMENT OF CANCER. |
| abstract | Quinazoline derivative of Formula I: ** Formula ** in which: R1 is selected from hydrogen, hydroxy, (C1-4) alkoxy and (C1-4) alkoxy (C1-5-4) alkoxy; each of G1, G2, G3 and G4 is independently selected from hydrogen and halogen; X1 is selected from SO2, CO, SO2N (R6) and C (R6) 2, where each R6 is independently selected from hydrogen and (C1-4) alkyl; Q1 is aryl or heteroaryl, said aryl or heteroaryl group having optionally one or more substituents independently selected from halogen, cyano, (C1-4) alkoxy and (C1-4) alkyl; R2 and R3, which may be the same or different, are selected from hydrogen, (C2-4) alkenyl, (C2-4) alkynyl and (C1-4) alkyl, where (C1-4) alkyl optionally has one or more hydroxy substituents, or R2 and R3 together with the carbon atom to which they are attached form a cyclopropyl ring; R4 and R5, which may be the same or different, are selected from hydrogen, (C3-4) alkenyl, (C3-4) alkynyl and (C1-4) alkyl, where (C1-4) alkyl optionally has one or more substituents independently selected from halogen, cyano, hydroxy, amino, (C 1-4) alkylamino, di- [C 1-4 alkyl] amino and (C 1-4) alkoxy, or R 4 and R 5 together with the nitrogen atom to which they are joined form a saturated, 4, 5, 6 or 7-membered heterocyclic ring, optionally containing one or more additional heteroatoms independently selected from oxygen, S, SO, SO2 and N (R7), where R7 is selected from hydrogen and (C1-4) alkyl, and where any heterocyclic ring formed by R4, R5 and the nitrogen atom to which they are attached optionally has one or more substituents independently selected from halogen, cyano, hydroxy, (C1-4) alkyl and alkoxy ( C1-4), and where any heterocyclic ring formed by R4, R5 and the nitrogen atom to which they are attached optionally has 1 or 2 oxo or thioxo substituents; or a pharmaceutically acceptable salt thereof. |
| priorityDate | 2005-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1156.